-

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

2024 Stifel Healthcare Conference
Presentation: Monday, November 18, 2024 at 9:10 a.m. ET
Location: New York, NY

2024 Jefferies London Healthcare Conference
Investor Meetings: Wednesday, November 20, and Thursday, November 21, 2024
Location: London, UK

7th Annual Evercore HealthCONx Conference
Fireside Chat: Thursday, December 5, 2024 at 9:10 a.m. ET
Location: Coral Gables, FL

About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Investors:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Investors:
Alex Straus
THRUST Strategic Communications
alex@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that management will participate in the following upcoming investor conferences in June. 2026 Jefferies Global Healthcare Conference Investor Meetings: Tuesday, June 2, 2026 Location: New York, NY 2026 UBS Virtual CNS Day Fireside Chat and Investor Meetings: Monday, June 15, 2026 Location: Virtual About Autobahn The...

Autobahn Therapeutics Announces U.S. FDA Fast Track Designation for Elunetirom, a CNS-Directed Thyroid Hormone Receptor Agonist, for the Adjunctive Treatment of Bipolar Depression

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to elunetirom, the Company’s lead candidate, for the adjunctive treatment of depressive episodes associated with bipolar I or bipolar II disorder in adults. Elunetirom is an oral, once daily, brain-penetrant, CNS thyroid hormone receptor...

Autobahn Therapeutics Presents New Preclinical Data at ASCP Annual Meeting Demonstrating Elunetirom Drives Robust Bioenergetic and Neuroplastic Improvements in Neuronal Cultures

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced the presentation of new preclinical data for elunetirom (ABX-002), the company’s lead asset currently in Phase 2 clinical development for adjunctive major depressive disorder (MDD) and bipolar depression, at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place in Miami Beach, F...
Back to Newsroom